 |
市場調查報告書
商品編碼
1378606
抗癲癇藥物市場：世代、給藥途徑、配銷通路和地區Antiepileptic Drugs Market, By Generation, By Route of Administration (Oral, Intravenous, Others ), By Distribution Channel, By Geography |
||||||
預計2023年全球抗癲癇藥物市場規模為70.1億美元，2030年將達88.1億美元，預測期內（2023-2030年）年度成長率（年複合成長率）預估為3.3%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 70.1億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期年複合成長率 | 3.30% | 2030年市場規模預測 | 88.1億美元 |
抗癲癇藥物是為患有癲癇發作的患者開立的。癲癇的主要症狀是反覆發作，這是大腦中突然爆發的電活動，暫時影響大腦功能。有些癲癇發作可能會導致您的身體抽搐，而有些癲癇發作可能會導致您失去意識或感到異常的感覺。抗癲癇藥物是一類多元化的藥物，擴大用於治療癲癇以外的疾病，例如預防偏頭痛、神經病變疼痛和雙相情感障礙。抗癲癇藥物分為三代：第一代、第二代、第三代。每一代都有不同的規格。第一代包括溴化物、苯巴比妥、撲米酮、卡馬西平，第二代包括非氨酯、拉莫三嗪、左乙拉西坦等，第三代包括拉科醯胺、醋酸艾斯利卡西平、氯巴札姆等。由於普及上升和這些藥物的採用不斷增加，預計第三代藥物在預測期內的年複合成長率最高。
市場動態
為了將創新新藥推向市場，主要企業正在努力採用核准等有機策略，預計這將在預測期內推動全球抗癲癇藥物市場的成長。例如，2022 年 3 月，生物製藥公司 UCB SA 宣布口服液 CIV FINTEPLA（芬氟拉明）將在美國食品藥物管理局上市，用於治療與腸漏症候群(LGS) 相關的癲癇發作2歲以上。宣布已獲得FDA核准。 LGS 是嚴重的兒童期發病的發育性癲癇性腦病變，其特徵是抗藥性癲癇發作。
本研究的主要特點
- 本報告對全球抗癲癇藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和復合年度（年複合成長率）。
- 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球抗癲癇藥物市場的主要企業。
- 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的資訊。
- 全球抗癲癇藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
- 相關人員可以透過用於分析全球抗癲癇藥物市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的和假設
- 這項研究的目的
- 假設
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章 市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 機會
- 主要進展
- 合併、收購和合作
- 最近的趨勢
- 最近推出/核准
- 法規場景
- 贖回場景
- PEST分析
- 波特的分析
第4章 全球抗癲癇藥物市場－新型冠狀病毒感染疾病（COVID-19）影響分析
- 經濟影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 對需求和供給的影響
第5章 2018-2030年全球抗癲癇藥物市場（世代）
- 第一代
- 第二代
- 第三代
第6章 全球抗癲癇藥物市場，依給藥途徑，2018-2030
- 口服
- 靜脈
- 其他
第7章 全球抗癲癇藥物市場，依配銷通路，2018-2030
- 醫院藥房
- 零售藥房
- 電子商務
第8章 2018-2030年全球抗癲癇藥物市場（按地區）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第9章 競爭形勢
- 公司簡介
- Novartis AG
- GlaxoSmithKline Plc
- Johnson &Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini Spa
- Sun Pharmaceutical Industries Ltd.
- UCB SA
- Marinus Pharmaceuticals, Inc.
- Sanofi SA
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts'Views
第10章 章
- 參考
- 調查方法
Global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 billion in 2023, and is expected to reach US$ 8.81 billion by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 3.3% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 7.01 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 3.30% | 2030 Value Projection: | US$ 8.81 Bn |
Anti-epileptic drugs are prescribed for patients who suffer from seizures. The major symptom of epilepsy is repeated seizures, which are sudden bursts of electrical activity in the brain that temporarily affects the functioning of the brain. Some seizures causes the body to jerk and shake, while others cause problems such as loss of awareness or unusual sensations. Anti-epileptic drugs include a diverse class of medications that are increasingly used for conditions apart from epilepsy such as migraine prophylaxis, neuropathic pain, and bipolar disorder. Anti-epileptics are categorized in three generations as first generation, second generation and third generation. Each generation denotes a different specification. The first generation drugs includes Bromide, Phenobarbital, Primidone, and Carbamazepine, second generation drugs include Felbamate, Lamotrigine, Levetiracetam, and others, and third generation drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam and others. The third generation drugs are anticipated to register the highest CAGR over the foreascted period attributed to rise in the rise in penetration and increasing adoption of these drugs.
Market Dynamics
In order to bring new and innovative drugs to the market, key players are engaged in adopting organic organic strategies such as regulatory approval which is expected to drive the global anti-epileptic drugs market growth over the forecast period. For instance, in March 2022, UCB S.A, a biopharmaceutical company, announced that FINTEPLA (fenfluramine), a oral solution CIV had been approved in theU.S., by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients of age two years and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures.
Key features of the study:
- This report provides an in-depth analysis of the global anti-epileptic drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global anti-epileptic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs market
Antiepileptic Drugs Market Detailed Segmentation:
- By Generation:
- First Generation
- Second Generation
- Third Generation
- By Route of Administration:
- Oral
- Intravenous
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co., Ltd.
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Key Developments
- Mergers, Acquisitions and Collaborations
- Recent Trends
- Recent Launches/Approvals
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Porter's Analysis
4. Global Antiepileptic Drugs Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Antiepileptic Drugs Market, By Generation, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
- Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
6. Global Antiepileptic Drugs Market, By Route of Administration, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
7. Global Antiepileptic Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
8. Global Antiepileptic Drugs Market, By Region, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth ,By Country, 2018 -2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and , Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts' Views
10. Section
- References
- Research Methodology
- About us and Sales Contact
